José G. Trujillo-Ferrara

Dr. José G. Trujillo-Ferrara

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in NeuroToxicology
Verified
Journal Article
Closed access
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua
EFEunice D. Farfán-García
Eunice D. Farfán-García
YLYessica López-Cabrera
Yessica López-Cabrera
EQEnrique Querejeta
Enrique Querejeta
JTJosé G. Trujillo-Ferrara
José G. Trujillo-Ferrara

1 January 2017 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
GTGABRIELA CARRASCO TORRES
GABRIELA CARRASCO TORRES
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
EAErik Andrade-Jorge
Erik Andrade-Jorge
SVSaúl Villa-Treviño
Saúl Villa-Treviño
JTJosé G. Trujillo-Ferrara
José G. Trujillo-Ferrara
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
The inflammatory condition of malignant tumors continually exposes cancer cells to reactive oxygen species, an oxidizing condition that leads to the activation of the antioxidant defense system. A similar activation occurs with glutathione production. This oxidant condition enables tumor cells to maintain the energy required for growth, proliferation, and evasion of cell death. The objective of the present study was to determine the effect on hepatocellular carcinoma cells of a combination treatment with maleic anhydride derivatives (prooxidants) and quercetin (an antioxidant). The results show that the combination of a prooxidant/antioxidant had a cytotoxic effect on HuH7 and HepG2 liver cancer cells, but not on either of two normal human epithelial cell lines or on primary hepatocytes. The combination treatment triggered apoptosis in hepatocellular carcinoma cells by activating the intrinsic pathway and causing S phase arrest during cell cycle progression. There is also clear evidence of a modification in cytoskeletal actin and nucleus morphology at 24 and 48 h posttreatment. Thus, the current data suggest that the combination of two anticarcinogenic drugs, a prooxidant followed by an antioxidant, can be further explored for antitumor potential as a new treatment strategy.

1 May 2003 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JTJosé G. Trujillo-Ferrara
José G. Trujillo-Ferrara
LCLeticia Montoya Cano
Leticia Montoya Cano
LEL. Michel Espinoza-Fonseca
L. Michel Espinoza-Fonseca

1 December 2018 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
YLYessica López-Cabrera
Yessica López-Cabrera
ECEmily L. Castillo-García
Emily L. Castillo-García
JAJosé A. Altamirano-Espino
José A. Altamirano-Espino
TPTeresa Pérez-Capistran
Teresa Pérez-Capistran
EFEunice D. Farfán-García
Eunice D. Farfán-García
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua

30 July 2018 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
EAErik Andrade-Jorge
Erik Andrade-Jorge
LSLuis A. Sánchez-Labastida
Luis A. Sánchez-Labastida
MSMarvin A. Soriano-Ursúa
Marvin A. Soriano-Ursúa
JGJuan A. Guevara-Salazar
Juan A. Guevara-Salazar
JTJosé G. Trujillo-Ferrara
José G. Trujillo-Ferrara

1 April 2003 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JTJosé G. Trujillo-Ferrara
José G. Trujillo-Ferrara
IVIván Vázquez
Iván Vázquez
JEJudith Espinosa
Judith Espinosa
RSRosa Santillan
Rosa Santillan
NFNorberto Farfán
Norberto Farfán
HHHerbert Höpfl
Herbert Höpfl